Lab launches 22 cancer tests

FORT MYERS — NeoGenomics has created tests to identify 22 categories of cancerous tumors that will help doctors treat their patients more effectively, the company announced.

The tests will help doctors identify the most effective therapy for that particular kind of tumor based on its genetic profile. The tumors range from those in the brain, lung, breast, esophagus and other kinds of cancers.

“Precision medicine requires precision testing,” says Doug VanOort, the NeoGenomics' chairman and CEO, in a statement. “Our targeted tests are responsive to the need for both comprehensive testing in complex cases and the need to be cost-sensitive for patients and insurance companies.”